Cannabics Pharmaceuticals and Purisys sign cannabinoid API supply agreement
The transaction will support Cannabics' planned IND fillings and Phase I/II (a) clinical trials
Purisys has agreed to supply Cannabics Pharmaceuticals, a global developer of cancer-related cannabinoid-based medicine, with GMP-grade APIs required for the manufacturing of its colorectal cancer treatment drug candidate.
According to Josh Hoerner, Purisys General Manager, the company will provide Cannabics with pharmaceutical-grade ultra-pure cannabinoid APIs for their drug candidate RCC-33 ― which is billed as the world’s first cannabinoid-based antitumour drug candidate for the treatment of colorectal cancer ― using state-of-the-art manufacturing technology.
In addition, the synthetically derived API manufacturer will also support Cannabics throughout an investigational new drug (IND) filing process, including providing all necessary regulatory and chemistry manufacturing and controls- (CMC) related support for its planned approach of the FDA.
APIs supplied under the agreement will be used by Cannabics ― a US public company with R&D capabilities based in Israel ― in Phase I/II (a) clinical studies that it is planning to launch in 2022.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
.png)
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
.png)
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
.png)
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
.png)
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance